Short answer · Medically reviewed summary · Last updated: 2026-05-08
Ruvalcaba syndrome is most commonly identified today as part of the broader Bannayan-Riley-Ruvalcaba syndrome (BRRS), a rare genetic disorder characterized by macrocephaly, intestinal hamartomatous polyps, and pigmented macules of the penis. Because the condition has been historically described under various names reflecting different clinical presentations, patients may encounter several synonyms in older medical records or international literature. What are the historical and alternative names for Ruvalcaba syndrome? In medical literature, Ruvalcaba syndrome has often been referred to by names that highlight specific clinical findings.
Ruvalcaba Syndrome synonyms
Other names for Ruvalcaba Syndrome: synonyms, acronyms and related terms used by doctors and patients.
Ruvalcaba syndrome is most commonly identified today as part of the broader Bannayan-Riley-Ruvalcaba syndrome (BRRS), a rare genetic disorder characterized by macrocephaly, intestinal hamartomatous polyps, and pigmented macules of the penis. Because the condition has been historically described under various names reflecting different clinical presentations, patients may encounter several synonyms in older medical records or international literature.
What are the historical and alternative names for Ruvalcaba syndrome?
In medical literature, Ruvalcaba syndrome has often been referred to by names that highlight specific clinical findings. Historically, it was described as Ruvalcaba-Myhre-Smith syndrome. Because it is now recognized as a phenotypic variant within the PTEN hamartoma tumor syndrome (PHTS) spectrum, it is frequently grouped under the umbrella of Bannayan-Riley-Ruvalcaba syndrome. Older texts may also refer to it as Myhre-Smith syndrome or Riley-Smith syndrome, reflecting the history of clinical case reports before the genetic link to the PTEN gene was established.
Why does Ruvalcaba syndrome have multiple names?
The naming of Ruvalcaba syndrome has evolved due to advancements in clinical genetics. Historically, clinicians identified distinct clusters of symptoms, such as intestinal polyps and macrocephaly, and assigned names based on the lead researchers of those cases. As genetic testing revealed that these conditions share a mutation in the PTEN gene, the medical community consolidated these into the classification of Bannayan-Riley-Ruvalcaba syndrome. This reclassification helps clinicians better understand the shared risks of the disease.
How is the condition classified in medical systems?
Major medical databases provide standardized codes to help navigate the terminology of Ruvalcaba syndrome:
- OMIM (Online Mendelian Inheritance in Man): Listed under #153480 as Bannayan-Riley-Ruvalcaba syndrome.
- Orphanet: Recognized as ORPHA:120 (Bannayan-Riley-Ruvalcaba syndrome).
- ICD-10/11: Often categorized under codes related to hamartomatous polyposis or PTEN-related disorders.
Next steps
- Consult with a clinical geneticist to confirm if your specific diagnosis of Ruvalcaba syndrome involves PTEN gene mutations.
- Join the 24 members of the Ruvalcaba syndrome community at DiseaseMaps.org to share experiences and find support.
- Request a referral to a gastroenterologist for regular surveillance of hamartomatous polyps.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Bannayan-Riley-Ruvalcaba syndrome.
- Orphanet: Rare disease database entry for ORPHA:120.
- OMIM: Entry #153480 regarding PTEN hamartoma tumor syndrome.
- PubMed: Clinical reviews on the phenotypic spectrum of PTEN-related disorders.
